zealand pharma obesity

Roche, obesity and Zealand

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

CNBC on MSN · 2d

Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

STAT · 2d

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital increase.

Fierce Biotech2d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Medical Dialogues10h

Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Roche, obesity and Zealand

Trending now